Abstract
In this double-blind, crossover study of 8 boys with minimal brain dysfunction, 20 mg of methylphenidate daily was significantly better than 160 mg of caffeine in controlling behavior, especially impulsivity and hyperactivity, and methylphenidate alone was superior to decaffeinated coffee and placebo. The tentative results of this study confirm the primary position of sympathomimetics in the pharmacotherapy of minimal brain dysfunction and, in addition, suggest the involvement of dopamine pathways in this disorder. The authors urge further study of this hypothesis.
Publication types
-
Clinical Trial
-
Comparative Study
-
Controlled Clinical Trial
MeSH terms
-
Administration, Oral
-
Attention Deficit Disorder with Hyperactivity / diagnosis
-
Attention Deficit Disorder with Hyperactivity / drug therapy*
-
Caffeine / administration & dosage
-
Caffeine / therapeutic use*
-
Child
-
Clinical Trials as Topic
-
Drug Administration Schedule
-
Drug Evaluation
-
Humans
-
Hyperkinesis / drug therapy
-
Male
-
Methylphenidate / administration & dosage
-
Methylphenidate / therapeutic use*
-
Placebos
-
Psychological Tests
-
Remission, Spontaneous
Substances
-
Placebos
-
Methylphenidate
-
Caffeine